Challenges for decision-makers when assessing within-class comparative effectiveness: the case of anticoagulation therapy for atrial fibrillation.

Briggs, Andrew; Howarth, Amanda; Davies, Shawn; Schneider, John; Spentzouris, Georgios; Mughal, Farhan; Fuat, Ahmet; Fay, Matthew

Briggs, Andrew; Howarth, Amanda; Davies, Shawn; Schneider, John; Spentzouris, Georgios; Mughal, Farhan; Fuat, Ahmet; Fay, Matthew.

Afiliação

Briggs A; London School of Hygiene & Tropical Medicine, London, UK.
Howarth A; Avalon Health Economics, Morristown, NJ 07960, USA.
Davies S; Avalon Health Economics, Morristown, NJ 07960, USA.
Schneider J; Avalon Health Economics, Morristown, NJ 07960, USA.
Spentzouris G; Avalon Health Economics, Morristown, NJ 07960, USA.
Mughal F; Daiichi Sankyo Europe Gmbh, Munich, Germany.
Fuat A; Daiichi Sankyo UK Ltd, Buckinghamshire, UK.
Fay M; Primary Care Physician, Carmel Medical Practice, Darlington, Durham, UK.

J Comp Eff Res ; 2022 Jan 24.

Article em En | MEDLINE | ID: mdl-35068197

Palavras-chave

cardiology/cardiovascular; comparative effectiveness research; costeffectiveness analysis; guideline development; health policy; meta-analysis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Systematic_reviews Idioma: En Revista: J Comp Eff Res Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google